Cigna Infliximab Users Get $500 To Switch To Biosimilars
Remicade Users Receive $500 Debit Card To Move Onto Preferred Drugs From Amgen And Pfizer
Executive Summary
Program aims to share rebate savings from preferred drugs, ease treatment disruptions. Products like Remicade covered under medical benefits require new kinds of incentives for switching.
You may also be interested in...
What’s Next? Five Things To Look Out For In July
In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.
Eight More Years: US Supreme Court Sinks Sandoz’ Hopes On Enbrel
Sandoz’ arguments urging the US Supreme Court to review patent litigation around Amgen’s Enbrel have fallen on deaf ears, blocking a route to market for biosimilar etanercept until 2029 in the US.
Medicare Part B Premium Reduction In 2023 Has Reserves Built In If Lecanemab Launches
But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.